249 related articles for article (PubMed ID: 2459218)
1. CR2 ligands modulate human B cell activation.
Bohnsack JF; Cooper NR
J Immunol; 1988 Oct; 141(8):2569-76. PubMed ID: 2459218
[TBL] [Abstract][Full Text] [Related]
2. Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM.
Carter RH; Fearon DT
J Immunol; 1989 Sep; 143(6):1755-60. PubMed ID: 2528579
[TBL] [Abstract][Full Text] [Related]
3. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.
Nemerow GR; McNaughton ME; Cooper NR
J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485
[TBL] [Abstract][Full Text] [Related]
4. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL.
Delibrias CC; Fischer E; Bismuth G; Kazatchkine MD
J Immunol; 1992 Aug; 149(3):768-74. PubMed ID: 1386093
[TBL] [Abstract][Full Text] [Related]
5. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
7. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes.
Fischer E; Delibrias C; Kazatchkine MD
J Immunol; 1991 Feb; 146(3):865-9. PubMed ID: 1703182
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells.
Hivroz C; Fischer E; Kazatchkine MD; Grillot-Courvalin C
J Immunol; 1991 Mar; 146(6):1766-72. PubMed ID: 1826011
[TBL] [Abstract][Full Text] [Related]
9. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells.
Servis C; Lambris JD
J Immunol; 1989 Apr; 142(7):2207-12. PubMed ID: 2784456
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD45 inhibition of human B cell proliferation depends on the nature of activation signals and the state of B cell activation. A study with anti-IgM and anti-CDw40 antibodies.
Gruber MF; Bjorndahl JM; Nakamura S; Fu SM
J Immunol; 1989 Jun; 142(12):4144-52. PubMed ID: 2470814
[TBL] [Abstract][Full Text] [Related]
11. Human B cell responsiveness to B cell growth factor after activation by phorbol ester and monoclonal anti-mu antibody.
Suzuki T; Butler JL; Cooper MD
J Immunol; 1985 Apr; 134(4):2470-6. PubMed ID: 2982946
[TBL] [Abstract][Full Text] [Related]
12. Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration.
Tsokos GC; Lambris JD; Finkelman FD; Anastassiou ED; June CH
J Immunol; 1990 Mar; 144(5):1640-5. PubMed ID: 2137840
[TBL] [Abstract][Full Text] [Related]
13. In vitro maturation of B cells in chronic lymphocytic leukemia. I. Synergistic action of phorbol ester and interleukin 2 in the induction of Tac antigen expression and interleukin 2 responsiveness in leukemic B cells.
Kabelitz D; Pfeffer K; von Steldern D; Bartmann P; Brudler O; Nerl C; Wagner H
J Immunol; 1985 Oct; 135(4):2876-81. PubMed ID: 2993419
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes.
Carter RH; Spycher MO; Ng YC; Hoffman R; Fearon DT
J Immunol; 1988 Jul; 141(2):457-63. PubMed ID: 2968402
[TBL] [Abstract][Full Text] [Related]
15. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV.
Luxembourg AT; Cooper NR
J Immunol; 1994 Nov; 153(10):4448-57. PubMed ID: 7525704
[TBL] [Abstract][Full Text] [Related]
16. Signaling through CD19, Fc receptors or transforming growth factor-beta: each inhibits the activation of resting human B cells differently.
Barrett TB; Shu GL; Draves KE; Pezzutto A; Clark EA
Eur J Immunol; 1990 May; 20(5):1053-9. PubMed ID: 1694130
[TBL] [Abstract][Full Text] [Related]
17. Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction.
Masucci MG; Szigeti R; Ernberg I; Hu CP; Torsteinsdottir S; Frade R; Klein E
Eur J Immunol; 1987 Jun; 17(6):815-20. PubMed ID: 3036539
[TBL] [Abstract][Full Text] [Related]
18. gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4).
Frade R; Myones BL; Barel M; Krikorian L; Charriaut C; Ross GD
Eur J Immunol; 1985 Dec; 15(12):1192-7. PubMed ID: 3878789
[TBL] [Abstract][Full Text] [Related]
19. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
[TBL] [Abstract][Full Text] [Related]
20. Human B cell activation. Effect of T cell cytokines on the physicochemical binding requirements for achieving cell cycle progression via the membrane IgM signaling pathway.
Mongini PK; Highet PF; Inman JK
J Immunol; 1995 Oct; 155(7):3385-400. PubMed ID: 7561033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
